Notícias e Atividades da Synthetic Biologics
Executivos
Veja o organograma con seus 7 executivos principais
Biografias mais buscadas da Synthetic Biologics
- Steven Shallcross, Chief Executive Officer, Chief Financial Office...
- Jeffrey Kraws, Chairman of the Board
- Jeffrey Wolf, Director
Criar um alerta
para seguir os movimentos de executivos da Synthetic Biologics.
Biotecnologia
Synthetic Biologics possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnologia
- Transcarent and Accolade have merged (publicado em 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Synthetic Biologics
- Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients | Theriva™ Biologics
- Theriva™ Biologics to Present at the 2025 NeauxCancer Conference | Theriva™ Biologics
- Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual | Theriva™ Biologics
- Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results | Theriva™ Biologics
- Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer | Theriva™ Biologics
- Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results | Theriva™ Biologics
- Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant | Theriva™ Biologics
- Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma | Theriva™ Biologics
- Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients | Theriva™ Biologics
- Theriva Biologics Announces Pricing of $2.5 Million Public Offering | Theriva™ Biologics
- View more press releases Close
Redes sociais sobre Synthetic Biologics
- Synthetic Biologics na Wikipedia, Google News e Yahoo Finance
- Synthetic Biologics na LinkedIn, Twitter e YouTube
